Buy Like Buffett
Watchlist

COHERENT CORP.

COHR · Healthcare · $44.0B mkt cap · FY2025 filings · · not refreshed in 39 days · Shallow moat ·

Doesn't clear the bar

Shallow moat
Share / Embed this score
Embed this score

The five investor questions

55

2021–2025 (latest 5 aligned FYs; v3 window cap 5): revenue $3.1B to $5.8B, increasing; diluted EPS 2.37 to -0.52, decreasing.

59

Median gross margin 37.9% over 10y, stable.

15

Median ROIC 8.4%, above the 12% hurdle in 0% of years.

—

Insufficient leverage/coverage inputs to score the balance sheet.

55

Owner earnings changed +10.6%/yr over up to the ten most recent annual observations.

The balanceSheet component abstained: Insufficient leverage/coverage inputs to score the balance sheet. The other four 20% weights were renormalized over the scored 80%.

Price vs. value if growth stopped today

A cautious baseline, not a price target: what the shares may support if normalized owner earnings simply hold steady.

Above value if growth stopped todayBelow value if growth stopped today
840% above value if growth stopped today
$421M
$30.04
$30.04
$282.39
840% above value if growth stopped today

What today’s price assumes: owner earnings growing ~57%/yr over 5 years. The zero-growth estimate assumes owner earnings stay flat (0% growth).

How to read this

We solve for the constant annual change in owner earnings that would make the five-year zero-growth estimate equal today’s price. This keeps the existing model inputs and calculation unchanged; it is an expectations lens, not a forecast.

This zero-growth estimate assumes trailing owner earnings persist — unreliable for declining businesses. The recent FY revenue series does not trigger the three-consecutive-declines flag.

Among the current top-score group, the median current price is 239% above the zero-growth estimate across 48 of the current top 50 companies by Moat Score with both values.

Score records captured Jul 26, 2026.

Exactly which 50 companies?

FTNT, META, MEDP, IBEX, MSFT, GOOGL, LULU, ANF, IDXX, TXRH, FHI, QLYS, FFIV, ADBE, LLY, MANH, VEEV, GRMN, SSD, MNST, DOCS, MCO, CPRT, NTAP, LRCX, NVDA, CORT, SFM, MPTI, ULTA, SN, RMD, ROL, PAYC, IRMD, INTU, DECK, MORN, LGCY, DAL, GWW, ISRG, MPWR, CTAS, LOPE, MRK, CMG, FAST, BKNG, ORLY

Missing a usable price or zero-growth estimate: ANF, BKNG.

Model details under moat-index@3.0.0: zero-growth multiple 11.1×, capped-growth comparison at no more than 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.

18 years of fundamentals

The business, in plain English

COHERENT CORP. booked $5.8B of revenue in FY2025 in the Healthcare sector and kept 35.2% of it as gross profit — a solid-margin business by that measure. After every other cost, 0.8% of each revenue dollar reached the bottom line.

Across the filed record, revenue grew from $292M (FY2009) to $5.8B (FY2025) — about 20.5% a year compounded over 16 years.

ROIC is not available for the latest filed year, FY2025. Across the full 13-year measurable filed record, median ROIC was 8.8%. Over the v3 recent window (9 measurable filed years), median ROIC was 8.4%. The Returns on Capital filter above scores it 15/100.

The balance sheet carried $3.7B of total debt in FY2025 against $162M of owner earnings — roughly 22.7 years of owner earnings to retire it all.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

FY2008–FY2025 · 18 fiscal years, normalized from COHR’s SEC filings

Sales, as filed$5.8B FY2025
$0$2.5B$5B2008201420202025
Revenue kept after cost of goods35.2% FY2025
0%20%40%2008201420202025
Standard ROIC or separately labeled Operating ROICROIC 0.9% FY2024
0%10%2008201420202025
Cash an owner could take out$162M FY2025
$0$250B$500B2008201420202025

Gaps in a line mean that item isn’t in COHR’s filings for that year. The series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Flagship explainer

How COHERENT CORP. makes its money

COHERENT CORP.'s filing does not supply enough comparable lines for a truthful flow chart — here's what is filed:

Table alternative
Filed lineValue% of revenueSource
$5.8B100%
Cost of revenue$3.8B65%
$2.0B35%
Income before tax$94.2M2%
Income tax$64.1M1%
$49.4M1%
Source: · event Jun 30, 2025 · retrieved Jul 26, 2026 · annual-row source set

Flagship explainer

What COHERENT CORP. owns — and owes

COHERENT CORP.'s filing tags don't support a full breakdown — here's what is filed:

Table alternative
Filed lineValue% of assetsSource
Total assets$14.9B100%
Cash and equivalents$909M6%
$3.7B25%
Stockholders’ equity$5.6B38%
Source: · event Jun 30, 2025 · retrieved Jul 26, 2026 · annual-row source set

Flagship explainer

What drives COHERENT CORP.’s return on equity?

One or more filed inputs needed for the five-factor decomposition are unavailable.

DuPont source inputs
InputValueFiscal yearSource
Net income$49.4MFY2025
Income before tax$94.2MFY2025
Operating incomeUnavailableFY2025
Revenue$5.8BFY2025
Ending assets$14.9BFY2025
Beginning assets$14.5BFY2024
Ending equity$5.6BFY2025
Beginning equity$5.2BFY2024
Source:
  • SEC filingFiling detailsAccession 0000820318-24-000016
  • SEC filingFiling detailsAccession 0000820318-25-000014
· event Jun 30, 2025 · retrieved Jul 26, 2026 · annual-row source set

Flagship explainer

Where COHERENT CORP.'s cash went

COHERENT CORP.’s filing does not supply enough provenance-matched cash-flow lines for a truthful flow chart — here’s what is filed:

Table alternative
Filed lineValue% of cash from operationsSource
Cash from operations$634M100%
Depreciation and amortization$554M87%
Source: · event Jun 30, 2025 · retrieved Jul 26, 2026 · annual-row source set

Curated 19-manager tier

Who reported holding COHERENT CORP.

Delayed public 13F reports for 2026-Q2—not live positions, trades, or recommendations.

0 holding0 exited1 not holding1/19 resolved18 not retrieved

Named manager positions and quarter-over-quarter changes
ManagerReported positionQuarter-over-quarterFiling accession
Markel / Markel-GaynerNo position reportedNo position reported
Abrams CapitalNot retrievedComparison not retrievedFiling not retrieved
Akre CapitalNot retrievedComparison not retrievedFiling not retrieved
Baupost GroupNot retrievedComparison not retrievedFiling not retrieved
Berkshire HathawayNot retrievedComparison not retrievedFiling not retrieved
Brave Warrior AdvisorsNot retrievedComparison not retrievedFiling not retrieved
Dodge & CoxNot retrievedComparison not retrievedFiling not retrieved
First EagleNot retrievedComparison not retrievedFiling not retrieved
FundsmithNot retrievedComparison not retrievedFiling not retrieved
Gardner Russo & QuinnNot retrievedComparison not retrievedFiling not retrieved
Gates Foundation TrustNot retrievedComparison not retrievedFiling not retrieved
Mairs & PowerNot retrievedComparison not retrievedFiling not retrieved
Oakmark / Harris AssociatesNot retrievedComparison not retrievedFiling not retrieved
Pershing SquareNot retrievedComparison not retrievedFiling not retrieved
Polen CapitalNot retrievedComparison not retrievedFiling not retrieved
Sequoia / Ruane CunniffNot retrievedComparison not retrievedFiling not retrieved
Southeastern Asset ManagementNot retrievedComparison not retrievedFiling not retrieved
Tweedy, BrowneNot retrievedComparison not retrievedFiling not retrieved
Yacktman Asset ManagementNot retrievedComparison not retrievedFiling not retrieved

Position size uses shares and filed value from each manager’s 13F. Portfolio weight uses the eligible long-share filing denominator. Changes compare only with the immediately preceding calendar quarter.

Source: · event Jun 30, 2026 · retrieved Jul 26, 2026

Flagship explainer

What COHERENT CORP. insiders reported

We could not retrieve insider activity for this rendering; no zero-activity claim is shown.

Unavailable: Form 4 activity could not be retrieved for this rendering.

Moat Score history

16 logged readings since Jul 17, 2026 · append-only, never rewritten

Moat Score over timeLast scored reading of each day, on the 0–100 scale45.8 / 100
0406080100WideNarrowShallowNo moatJul 20, 2026Jul 26, 2026

Breaks in the line mark methodology or normalizer upgrades — readings across versions aren’t compared, so a level shift there isn’t a change in the business.

Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars

  1. Normalizer upgraded unstamped (version unknown)moat-xbrl-normalizer@1.1.0 — readings across versions aren’t comparedJul 26, 2026
  2. Methodology upgraded moat-index@2.0.0moat-index@3.0.0 — readings across versions aren’t comparedJul 23, 2026
  3. Methodology upgraded moat-index@1.2.0moat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026

Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.

Insider activity

Form 4 reports mix P/S market or private transactions with compensation-plan mechanics. Activity casually described as “insider selling” can include compensation mechanics; awards, tax withholding, and option exercises are shown by their exact filed class here, never collapsed into “Bought” or “Sold.”

These are disclosed filing facts and arithmetic aggregates, not a signal or verdict.

The insider-filing service is temporarily unavailable, so no partial or guessed answer is shown for COHR.

Track record

How COHERENT CORP.’s moat rated in each of the years we can reconstruct from its filings — scored only on what was knowable at the time — and what its price and returns did afterward. The score never saw a price; the two are joined only in hindsight, for education, not as a signal.

Point-in-time scores 2011–2025, one methodology version · reconstructed from filings on file each Dec 31 — never with hindsight

Point-in-time Moat Score (dot colored by tier)Indexed price (total-return (dividends reinvested))Rated Wide-moat that year

How to read this: each dot is what the engine would have scored COHR on that December 31; the line below is its total-return price path (dividends reinvested) in the years since.

0406080100WideNarrowShallowNo moatPoint-in-time Moat Score1002005001,000Indexed price · log scale (2012 = 100)201120142017202020232026

Two tracks, one timeline: the score has its own 0–100 scale (top), the price its own 100-based scale (bottom) — never a shared axis. The price path is a total-return (dividends reinvested) index built from the same data the forward returns use; gaps in the score line are years with no reconstructed rating (see the table for why). The Table view carries every value.

What followed, in the years it rated Wide

In the 1 year COHR rated Wide-moat (2011), the median forward total return that followed — measured only after each year’s filings were public — was:

  • 1 year 7% vs the S&P 500’s 15% (price basis) · median over 1 year
  • 3 years −23% vs the S&P 500’s 61% (price basis) · median over 1 year
  • 5 years 67% vs the S&P 500’s 77% (price basis) · median over 1 year

These are medians computed from the data, not a claim about any one year. The company figures are total returns (dividends reinvested); the S&P 500 is the price-only ^GSPC index, which excludes dividends and so understates the index — the gap flatters the company. A quality rating is not a return forecast, and past returns don’t predict future ones. Educational only, not investment advice.

Healthcare context

#244 of 710 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

  1. #242RYTM RHYTHM PHARMACEUTICALS, INC.46.0Shallow moat
  2. #243PAHC Phibro Animal Health Corporation45.9Shallow moat
  3. #245LEXX LEXARIA BIOSCIENCE CORP.45.8Shallow moat
  4. #246CTKB CYTEK BIOSCIENCES, INC.45.7Shallow moat

Compare COHR with its nearest peers →All Healthcare companies on the Index →

Common questions about COHR

Does COHERENT CORP. have an economic moat?
Based on its FY2025 SEC filings, the Moat Index scores COHERENT CORP. (COHR) 45.8 out of 100 — a Shallow moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 55, pricing power 59, returns on capital 15, balance-sheet safety not measurable from the filings, capital allocation 55.
Is COHR trading below the conservative owner-earnings estimate?
The value if growth stopped today — a zero-growth baseline — is $30.04 per share. It capitalizes normalized owner earnings at a 9% rate and assumes 0% growth. Versus a recent price of $282.39, that is 840% above value if growth stopped today. The model also publishes a capped-growth comparison, but the zero-growth estimate is the cautious baseline. It assumes trailing owner earnings persist and is unreliable for declining businesses. This is an educational estimate from primary SEC filings, not intrinsic value as a fact or investment advice.
How has COHR's Moat Score changed over time?
The record logs 16 readings since Jul 17, 2026; the latest reads 45.8 out of 100 (shallow moat). No tier changes on record yet. (Methodology or normalizer upgrades on Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell COHR. See the disclaimer.